‘Global Cystic Fibrosis Market Worth $7.7bn In 2021’ Says Visiongain Report

30 August 2018

Visiongain’s new report the Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies indicates that the Global Cystic Fibrosis market will see $7.7bn in spending in 2021.

The lead analyst of the report said: “The cystic fibrosis market is poised for a rapid growth year-on-year. The major driver of cystic fibrosis market is the new product launches in CFTR modulator class. The market share of CFTR modulator therapies is nearly half at 51% of the total therapeutic share in 2016. Visiongain expects the global cystic fibrosis market to grow at a very strong pace of CAGR 16.7% from 2016 until 2021. This growth is mainly driven by the expected rapid uptake of Orkambi (Vertex Pharmaceuticals).”

The 191 page report contains 113 tables, charts and graphs that add visual analysis in order to explain developing trends within the Global Cystic Fibrosis market. Visiongain provides revenue forecasts for the period 2016-2026 as well as qualitative analyses for the leading segments of this market, which include:

o Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
o Protein Transcription Modulators
o Pancreatic Enzyme Products (PEP)
o Other therapies

This report offers individual drug forecast and analysis of the 9 leading cystic fibrosis drugs. In addition, this report provides patent analysis of marketed and pipeline products for cystic fibrosis.

This 191 page report provides revenue, growth forecasts and discussion of relevant trends and developments in the leading national cystic fibrosis market. The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe are also discussed.

The Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies report will be of value to anyone who wants to better understand the Cystic Fibrosis market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Cystic Fibrosis market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020


Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020


Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020


Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020